KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Elective Nodal Radiation Therapy in Localized Prostate Cancer: A Meta-Analysis. PMID 42176865 · Int J Radiat Oncol Biol Phys · 2026-May-22 The record is a meta-analysis of Phase III randomized trials, but it does not meet the drug intervention criterion (radiation therapy only) and is not an original result report.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study. PMID 42176706 · J Am Acad Dermatol · 2026-May-22 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Developing and evaluating the effectiveness of a web-based application to improve the mental health of infertile women: a multi-phase study protocol. PMID 42174619 · Reprod Health · 2026-May-22 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Clinical, radiographic, and histological evaluation of autogenous demineralized dentin matrix versus xenograft in alveolar ridge preservation: a randomized controlled trial. PMID 42174333 · Int J Implant Dent · 2026-May-22 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Depemokimab reduces asthma exacerbations similarly to other biologics. PMID 42173441 · Ann Allergy Asthma Immunol · 2026-May-22 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of a Personalized Mobile Health Intervention Using Artificial Intelligence (the WARIFA App) Versus a Nonpersonalized Intervention on User-Defined Objectives, Healthy Lifestyles, and Management of Type 1 Diabetes (T1D): Protocol for a Randomized Controlled Trial. PMID 42172625 · JMIR Res Protoc · 2026-May-22 The record describes a protocol for a randomized controlled trial evaluating a mobile health app (WARIFA) with AI-driven personalized messages versus a nonpersonalized version. It is not an oncology trial, does not involve a drug intervention, does not report time-to-event efficacy data (primary endpoint is a Likert-scale goal assessment), and results are pending (data analysis ongoing). Therefore, it does not meet the eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study. PMID 42000149 · Vaccine · 2026-May-22 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials. PMID 42415265 · Intest Res · 2026-May-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Total Neoadjuvant Therapy, Organ Preservation and Beyond: A State-of-the-Art Systematic Review and Critical Appraisal of Locally Advanced Rectal Cancer Management. PMID 42187894 · Diseases · 2026-May-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-Term Outcomes After Proton Therapy Versus Intensity Modulated Photon Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Post Hoc Analysis of a Prospective Randomized Trial. PMID 42173326 · Int J Radiat Oncol Biol Phys · 2026-May-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study. PMID 42168759 · Head Neck · 2026-May-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial. PMID 42168180 · Nat Commun · 2026-May-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data. PMID 42167880 · Lupus Sci Med · 2026-May-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
mHealth-Supported Exercise Rehabilitation to Reverse Frailty After Autologous Transplantation in Multiple Myeloma: Randomized Controlled Trial. PMID 42166768 · JMIR Mhealth Uhealth · 2026-May-21 The study is an original randomized controlled trial in multiple myeloma survivors, but it is not a Phase III/IIIb or Phase II/III trial (phase not specified, likely early or supportive care), it does not have a drug-containing intervention (exercise rehabilitation only), and its primary/secondary endpoints are not time-to-event efficacy outcomes (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Protocol digest of a randomized controlled trial comparing transverse colectomy with extended right hemicolectomy for Stage II/III transverse colon cancer: JCOG2304 (TACTICS). PMID 42166219 · Jpn J Clin Oncol · 2026-May-21 The record describes a phase III randomized trial in oncology with a time-to-event endpoint, but the intervention is surgical (no drug-containing arm) and the publication is a protocol digest without results, making it ineligible.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials. PMID 42163822 · Acta Derm Venereol · 2026-May-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A randomized controlled trial comparing robotic NOSES versus robotic TME for Mid-rectal cancer: short-term oncological and perioperative outcomes. PMID 42162355 · J Robot Surg · 2026-May-21 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Topical clobetasol propionate 0.025% oral gel in the treatment of oral lichen planus: a double-blind, randomized placebo-controlled trial. PMID 42163196 · BMC Oral Health · 2026-May-20 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Perioperative nebulized budesonide and L-Cysteine reduce pulmonary complications after posterior skull base tumor resection: a randomized controlled trial. PMID 42163118 · BMC Anesthesiol · 2026-May-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old. PMID 41560517 · Clin Infect Dis · 2026-May-20 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Five-year survival with tebentafusp in metastatic uveal melanoma. PMID 42162665 · Ann Oncol · 2026-May-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial. PMID 42162664 · Ann Oncol · 2026-May-19 The study is a randomized Phase III trial in human oncology with a drug intervention, but its primary efficacy endpoint is pathologic complete response (pCR), which is a categorical binary outcome, not a time-to-event endpoint. No time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP) or associated Kaplan-Meier/HR results are reported in the provided abstract. Therefore, it does not meet the time-to-event efficacy endpoint criterion for inclusion.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cryoablation for early-stage invasive breast cancer: pathologic and imaging outcomes from the prospective FIRST trial. PMID 42157305 · Breast Cancer Res · 2026-May-19 The study is a prospective, non-randomized, single-arm Phase II trial evaluating cryoablation for early-stage breast cancer. It does not meet key eligibility criteria: it is not randomized, is Phase II (not Phase III/IIIb or Phase II/III), uses a non-drug intervention (cryoablation), and its primary efficacy endpoint is pathologic ablation rate, not a time-to-event outcome.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Infographic: Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, Phase 3 trial. PMID 42156919 · Eye (Lond) · 2026-May-19 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial. PMID 42154367 · Adv Ther · 2026-May-19 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial. PMID 42132192 · J Am Heart Assoc · 2026-May-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Stereotactic body radiotherapy plus sunitinib vs. sunitinib alone in treatment-naive oligometastatic renal cell carcinoma: A phase 2 clinical trial. PMID 42013852 · Cell Rep Med · 2026-May-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial. PMID 41697953 · Br J Dermatol · 2026-May-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B. PMID 42165759 · JACC Asia · 2026-May-18 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Dupilumab in COPD: A Pooled Analysis of Emergency Department Visits, Hospital Admissions, and Systemic Corticosteroid Use. PMID 42153327 · Am J Respir Crit Care Med · 2026-May-18 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Artificial intelligence-assisted integrated care to promote colonoscopy uptake (AICC) in China: study protocol for a cluster randomized controlled trial. PMID 42152022 · Trials · 2026-May-18 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A national, multicentre, randomised, controlled, parallel-arms, phase III clinical trial of neoadjuvant FOLFOXIRI and chemoradiotherapy versus neoadjuvant CAPOX/FOLFOX and chemoradiotherapy in patients with high-risk locally advanced rectal cancer: study protocol of the MEND-IT II trial. PMID 42151882 · BMC Cancer · 2026-May-18 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of trial exclusion criteria on real-world comparative effectiveness of targeted therapies in rheumatoid arthritis: the FIRST Registry. PMID 42150842 · RMD Open · 2026-May-18 The study is a registry-based observational analysis of real-world effectiveness in rheumatoid arthritis, not an oncology trial. It is not a randomized controlled trial reporting results from a Phase III/IIIb or Phase II/III drug intervention trial with a primary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant Immune Checkpoint Inhibitors in Head and Neck Cancer: A Meta-Analysis of Phase III Trials. PMID 42150812 · J Oral Pathol Med · 2026-May-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial. PMID 42149133 · Clin Cancer Res · 2026-May-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Nerandomilast for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: Clinical Efficacy, Safety, and Place in Therapy. PMID 42145068 · Ann Pharmacother · 2026-May-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults. PMID 41692601 · Aesthet Surg J · 2026-May-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Hepatic arterial infusion pump chemotherapy combined with systemic therapy versus systemic therapy alone as induction treatment for initially unresectable colorectal liver metastases: a study protocol of the randomised controlled trial - PUMP-IT RCT. PMID 42143303 · BMC Cancer · 2026-May-16 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Rimegepant for the acute treatment of migraine: a systematic review and meta-analysis. PMID 42143245 · J Headache Pain · 2026-May-16 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials). PMID 42142212 · Rheumatol Ther · 2026-May-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Exploring the context, mechanisms, and outcomes of school-based group interpersonal therapy for depressed adolescents in Nepal: Analysis of qualitative process data from a pilot realist cluster-randomized controlled trial. PMID 42141835 · Psychother Res · 2026-May-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial. PMID 42140950 · Nat Commun · 2026-May-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial. PMID 42134354 · Lancet · 2026-May-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial. PMID 42114550 · Lancet · 2026-May-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Feasibility, acceptability and efficacy of a nurse-led palliative care health coaching intervention (Educate, Nurture, Advise before Life Ends) for patients with heart failure and their caregivers in Singapore: a randomised wait-list controlled pilot study of health coaching in Asian heart failure. PMID 42152453 · BMJ Open · 2026-May-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Anti-C5a Antibody STSA-1002 for Patients With ARDS Due to Viral Pneumonia: A Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 42142803 · Chest · 2026-May-15 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Does Radiation Boost Dose Affect Organ Preservation Rates? A Secondary Analysis of the Organ Preservation in Patients With Rectal Adenocarcinoma Trial. PMID 42142103 · Int J Radiat Oncol Biol Phys · 2026-May-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A randomized, open-label phase II non-inferiority study of niraparib maintenance after 3 versus 6 cycles of platinum-based chemotherapy in patients with completely debulked advanced HRD-positive high-grade ovarian cancer in first-line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62). PMID 42140839 · Int J Gynecol Cancer · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons. PMID 42138781 · Adv Ther · 2026-May-15 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters. PMID 42138077 · J Clin Invest · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -